RIGLRIGEL PHARMACEUTICALS INC
Pharmaceutical Preparations
- Revenue
- $294M
- 64% YoY
- Operating margin
- 42.6%
- 216% YoY
- EBITDA
- $128M
- 384% YoY
- Market cap
- $940M
- Employees
- 10,000
- $29K revenue each
- Net debt / EBITDA
- -0.1×
- −$16M net debt
- AI in 10-K
- 3.5
- mentions per 10K words
Takeover score 3 of 13
Fixable underperformance 1 of 7
- TSR below peersNo—3+ of last 5 years
- High CEO pay despite TSRNo—Median CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashYes21% of net incomeCash flow under 80% of net income
- Dilutive SBCNo4% of revenueOver 10% of revenue
- Payouts exceed cash flowNo0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyNo—Over 40% of assets
- Shareholder dissentNo—Any vote under 80% support
Buyer economics 2 of 4
- Low revenue per employeeNo$29K · 27th pctBottom quartile of its SIC industry
- Quiet on AINo3.5 per 10K words · 75th pctBottom quartile of AI mentions in 10-Ks
- Net cashYesNet cash · 0.1× EBITDAMore cash than debt, positive EBITDA
- Buyout-sizedYes$940M market capMarket cap $500M–$5B
Catalysts 0 of 2
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingNo−$306K netNet sales over $10M in 12 months
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $149M | $120M | $117M | $179M | $294M | 64% |
| Operating income | −$12M | −$56M | −$20M | $24M | $125M | 419% |
| Net income | −$18M | −$59M | −$25M | $17M | $367M | 1999% |
| Operating cash flow | $6M | −$74M | −$6M | $31M | $76M | 140% |
| Capex | $627K | $450K | — | — | — | |
| Stock-based comp | $9M | $12M | $9M | $12M | $13M | 2.6% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $306K · 3
- Net
- −$306K
Pay vs performance
No pay-versus-performance disclosure yet.